Acadian Asset Management
PLX icon

Acadian Asset Management’s Protalix BioTherapeutics PLX Stock Holding History

Acadian Asset Management’s Portfolio PLX Stock Details PLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-9,691
Closed -$24K – 1794
2025
Q1 		$24K Buy
+9,691
New +$23.1K ﹤0.01% 1517

Other funds holding PLX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Connor, Clark & Lunn Investment Management (CC&L)
Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $43.4B AUM 51.29% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
SWP
Stratos Wealth Partners Beachwood, Ohio $8.8B AUM 21.82% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Acadian Asset Management's PLX Position: Q2 2025 in Review

Acadian Asset Management sold out of Protalix BioTherapeutics (PLX) in Q2 2025, closing a stake of 9,691 shares — an estimated $24K sold.

Acadian Asset Management first reported a position in PLX in Q1 2025 and held it in 1 quarter. The position peaked at $24K in Q1 2025. 63 funds tracked by Wall St. Rank hold PLX as of Q2 2025.

  • Acadian Asset Management reported no remaining Protalix BioTherapeutics position as of Q2 2025 after selling out during the quarter.
  • Acadian Asset Management sold 9,691 Protalix BioTherapeutics shares in Q2 2025, an estimated $24K.
  • Acadian Asset Management first reported a position in Protalix BioTherapeutics in Q1 2025 and held it in 1 quarter.
  • Acadian Asset Management's Protalix BioTherapeutics position peaked at $24K in Q1 2025.
  • 63 funds tracked by Wall St. Rank held Protalix BioTherapeutics as of Q2 2025.

Based on Acadian Asset Management's 13F filing for Q2 2025, filed 7 Aug 2025.